Overview

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Status:
Recruiting

Trial end date:
2025-11-07

Target enrollment:

Participant gender:

Summary

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

AstraZeneca K.K.